Prime Medicine, Inc. is a biotech firm that employs gene editing technology to combat diseases using genetic therapies. Their Prime Editors deliver the desired genetic edit by combining a Cas protein with a reverse transcriptase enzyme through a pegRNA that targets the genomic location. The company is based in Cambridge, Massachusetts and was founded in 2019.